logo

INSM

Insmed·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

INSM fundamentals

Insmed (INSM) released its earnings on Oct 30, 2025: revenue was 142.00M (YoY +52.00%), beat estimates; EPS was -1.75 (YoY -37.80%), missed estimates.
Revenue / YoY
142.00M
+52.00%
EPS / YoY
-1.75
-37.80%
Report date
Oct 30, 2025
INSM Earnings Call Summary for Q3,2025
  • BRINSUPRI Launch Momentum: $28M in 6 weeks, 2,550 patients, and broad prescriber adoption, despite early-stage uncertainty.
  • Pipeline Progress: EU brensocatib approval expected in 2025, BiRCh and CEDAR trials on track, and TPIP Phase III启动.
  • Financial Strength: $1.7B cash, ARIKAYCE guidance raised to $420-430M, and robust pipeline funding.
  • Clinical Catalysts: ENCORE readout in 2026, BiRCh results in early 2026, and multiple Phase III starts in 2026.
EPS
Revenue

Revenue & Expenses

INSM has released its 2025 Q3 earnings report, with revenue of 142.34M, reflecting a YoY change of 52.36%, and net profit of -370.02M, showing a YoY change of -67.79%. The Sankey diagram below clearly presents INSM's revenue sources and cost distribution.

Key Indicators

Insmed (INSM) key financial stats and ratios, covering profitability, financial health, and leverage.
Insmed (INSM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Insmed (INSM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Insmed (INSM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Insmed (INSM) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Insmed (INSM) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield